Swiss pharmaceutical giant Novartis said Wednesday it would not hike drug prices in the United States this year, following a similar decision by rival Pfizer amid pressure from the White House.
Jul 18, 2018
0
0
The U.S. Food and Drug Administration (FDA) has expanded approval for a personalized cellular therapy developed at the University of Pennsylvania's Abramson Cancer Center, this time for the treatment of adult patients with ...
May 01, 2018
0
128
Two new analyses of data from more than 10,000 heart attack survivors worldwide were presented by investigators from Brigham and Women's Hospital at the 2018 American College of Cardiology meeting. Paul Ridker, MD, director ...
Mar 12, 2018
0
1
(HealthDay)—Secukinumab is safe and effective as a treatment for patients with extensive moderate-to-severe scalp psoriasis, according to a study published in the October issue of the Journal of the American Academy of ...
Sep 29, 2017
0
0
Opening a new era in cancer care, U.S. health officials have approved a breakthrough treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia.
Aug 31, 2017
0
124
When doctors talk about a new leukemia drug from Novartis, they ooze enthusiasm, using words like "breakthrough," "revolutionary" and "a watershed moment."
Aug 24, 2017
0
3
Greece's justice minister on Tuesday promised a "swift and thorough" investigation into suspected corruption by civil servants and Swiss pharmaceutical giant Novartis.
Jan 03, 2017
0
0
Prosecutors have indicted the former chief executive of the South Korean unit of Novartis and five other former and current managers over allegations they illegally paid doctors 2.6 billion won ($2.3 million) in return for ...
Aug 13, 2016
0
2
Swiss pharmaceutical giant Novartis risks seeing some of its medicines banned in South Korea after company executives were charged with offering illegal discounts to doctors, the Financial Times reported Thursday.
Aug 11, 2016
0
0
Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals.
May 18, 2016
0
8
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number one in revenues, which accounted over $53 billion in 2008, and number three in sales, which accounted 36.172 billon in 2008 . Novartis is one of the largest healthcare companies in the world and a leading giant among pharmaceutical companies. Novartis manufactures drugs such as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec / Glivec), cyclosporin A (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Novartis owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
This text uses material from Wikipedia, licensed under CC BY-SA
